Literature DB >> 20170376

Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Adriana Weinberg1, Ann A Lazar, Gary O Zerbe, Anthony R Hayward, Ivan S F Chan, Rupert Vessey, Jeffrey L Silber, Rob R MacGregor, Kenny Chan, Anne A Gershon, Myron J Levin.   

Abstract

BACKGROUND: Varicella-zoster virus (VZV)-specific cell-mediated immunity is important for protection against VZV disease. We studied the relationship between VZV cell-mediated immunity and age after varicella or VZV vaccination in healthy and human immunodeficiency virus (HIV)-infected individuals.
METHODS: VZV responder cell frequency (RCF) determinations from 752 healthy and 200 HIV-infected subjects were used to identify group-specific regression curves on age.
RESULTS: In healthy individuals with past varicella, VZV RCF peaked at 34 years of age. Similarly, VZV-RCF after varicella vaccine increased with age in subjects aged <1 to 43 years. In subjects aged 61-90 years, VZV RCF after zoster vaccine decreased with age. HIV-infected children had lower VZV RCF estimates than HIV-infected adults. In both groups, VZV RCF results were low and constant over age. Varicella vaccination of HIV-infected children with CD4 levels 20% generated VZV RCF values higher than wild-type infection and comparable to vaccine-induced responses of healthy children.
CONCLUSIONS: In immunocompetent individuals with prior varicella, VZV RCF peaked in early adulthood. Administration of varicella vaccine to HIV-infected or uninfected individuals aged >5 years generated VZV RCF values similar to those of immunocompetent individuals with immunity induced by wild-type infection. A zoster vaccine increased the VZV RCF of elderly adults aged <75 years to values higher than peak values induced by wild-type infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170376      PMCID: PMC3136368          DOI: 10.1086/651199

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Mixed effects models with censored data with application to HIV RNA levels.

Authors:  J P Hughes
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Selective decline in cellular immune response to varicella-zoster in the elderly.

Authors:  A E Miller
Journal:  Neurology       Date:  1980-06       Impact factor: 9.910

3.  Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.

Authors:  Adriana Weinberg; Myron J Levin; Rob Roy Macgregor
Journal:  Hum Vaccin       Date:  2010-04-15

4.  Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study.

Authors:  Sara L Thomas; Jeremy G Wheeler; Andrew J Hall
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

5.  Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures.

Authors:  Rodolphe Thiébaut; Hélène Jacqmin-Gadda; Catherine Leport; Christine Katlama; Dominique Costagliola; Vincent Le Moing; Philippe Morlat; Geneviève Chêne
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

6.  Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.

Authors:  Shu Li; Ivan S F Chan; Holly Matthews; Joseph F Heyse; Christina Y Chan; Barbara J Kuter; Karen M Kaplan; S J Rupert Vessey; Jerald C Sadoff
Journal:  Pediatr Infect Dis J       Date:  2002-04       Impact factor: 2.129

7.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

8.  Ten year follow-up of healthy children who received one or two injections of varicella vaccine.

Authors:  Barbara Kuter; Holly Matthews; Henry Shinefield; Steve Black; Penelope Dennehy; Barbara Watson; Keith Reisinger; Lee Lian Kim; Lisa Lupinacci; Jonathan Hartzel; Ivan Chan
Journal:  Pediatr Infect Dis J       Date:  2004-02       Impact factor: 2.129

9.  Specificity of the blastogenic response of human mononuclear cells to herpesvirus antigens.

Authors:  J A Zaia; P L Leary; M J Levin
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

10.  Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Andrew A Wiznia; Bonnie J LaFleur; Sona Shah; Myron J Levin
Journal:  J Infect Dis       Date:  2004-06-09       Impact factor: 5.226

View more
  38 in total

1.  Integration of immunity with physical and cognitive function in definitions of successful aging.

Authors:  Patricia Griffin; Joshua J Michel; Kristy Huysman; Alison J Logar; Abbe N Vallejo
Journal:  Aging Dis       Date:  2012-02-27       Impact factor: 6.745

2.  Immune aging and challenges for immune protection of the graying population.

Authors:  Abbe N Vallejo
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

3.  Herpes zoster increased risk of neuralgic amyotrophy: a retrospective, population-based matched cohort study.

Authors:  Tsung-Yen Ho; Chi-Hsiang Chung; Yu-Ping Shen; Liang-Cheng Chen; Wu-Chien Chien; Yung-Tsan Wu
Journal:  J Neurovirol       Date:  2018-11-05       Impact factor: 2.643

4.  Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination.

Authors:  Christiane S Eberhardt; Andreas Wieland; Tahseen H Nasti; Alba Grifoni; Elizabeth Wilson; D Scott Schmid; Bali Pulendran; Alessandro Sette; Edmund K Waller; Nadine Rouphael; Rafi Ahmed
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 5.  Herpes zoster and the search for an effective vaccine.

Authors:  N Arnold; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

Review 6.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 7.  Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Authors:  Ian H Frazer; Myron J Levin
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

Review 8.  The Pathobiology of Skin Aging: New Insights into an Old Dilemma.

Authors:  Eleanor Russell-Goldman; George F Murphy
Journal:  Am J Pathol       Date:  2020-04-01       Impact factor: 4.307

9.  Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy.

Authors:  Akinao Okamoto; Akihiro Abe; Masataka Okamoto; Tsukane Kobayashi; Tomohiko Terazawa; Yoko Inaguma; Masutaka Tokuda; Masamitsu Yanada; Satoko Morishima; Tadaharu Kanie; Yukiya Yamamoto; Motohiro Tsuzuki; Yoshiki Akatsuka; Shuichi Mizuta; Tetsushi Yoshikawa; Nobuhiko Emi
Journal:  Int J Hematol       Date:  2012-08-18       Impact factor: 2.490

10.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.